Radiation necrosis following proton therapy successfully treated by low‐dose bevacizumab in a patient with relapsed anaplastic ependymoma

Saito, Shoji; Miyairi, Yosuke; Araya, Masayuki; Yomo, Shoji; Kuwabara, Haruki; Uchida, Eriko; Watanabe, Tatsuo; Kurata, Tadao; Sakashita, Kazuo; Shigeta, Hiroaki

doi:10.1002/pbc.27088

Cited by 1 publication

(1 citation statement)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A recent prospective multicenter clinical trial of Bev in patients with symptomatic radiation necrosis demonstrated that Bev immediately alleviated perilesional edema and achieved a high cumulative remission rate [ 18 ]. In addition, regarding cases of radiation necrosis following PBT, some previous reports mentioned the effectiveness of Bev [ 19 , 20 ]. To implement high-dose PBT, it is essential to establish an effective treatment strategy centered on Bev.…”

Section: Discussionmentioning

confidence: 99%

High-dose proton beam therapy versus conventional fractionated radiation therapy for newly diagnosed glioblastoma: a propensity score matching analysis

et al. 2023

View full text Add to dashboard Cite

Background High-dose proton beam therapy (PBT) uses excellent dose concentricity based on the unique characteristic termed the Bragg peak. PBT is a highly feasible treatment option that improves survival in select patients with newly diagnosed glioblastoma (GBM). However, selection bias remains an issue in prior studies that evaluated the efficacy of PBT. The aim of the present study was to compare the survival outcomes and toxicities of high-dose PBT and conventional radiation therapy (CRT) using propensity score-matched treatment cohorts. Methods The analysis included patients with newly diagnosed GBM treated with high-dose PBT of 96.6 Gy (RBE) or CRT of 60 Gy from 2010 to 2020. Propensity score generation and 1:1 matching of patients were performed based on the following covariates: age, sex, tumor location, extent of resection, chemotherapy, immunotherapy, and pre-radiation Karnofsky performance scale score. Results From a total of 235 patients, 26 were selected in each group by propensity score matching. The median overall survival (OS) of the PBT group was 28.3 months, while the median OS of the CRT group was 21.2 months. Although acute radiation-related toxicities were equivalent between the PBT and CRT groups, radiation necrosis as a late radiation-related toxicity was observed significantly more frequently in the PBT group. Conclusions High-dose PBT provided significant survival benefits for patients with newly diagnosed GBM compared to CRT as shown by propensity score matching analysis. Radiation necrosis remains an issue in high-dose PBT; thus, the establishment of an effective treatment strategy centered on bevacizumab would be essential.

show abstract

Section: Discussionmentioning

confidence: 99%